Full notification file
Member State to which the notification was sent
Date of acknowledgement from the Member State Competent Authority
Title of the Project
A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected UshStat® Administered to Patients with Retinitis Pigmentosa Associated with Usher Syndrome Type 1B (US1/001/10)
Proposed period of release:
01/09/2013 to 31/08/2015
Name of the Institute(s) or Company(ies)
Oxford BioMedica UK Ltd., Medawar Centre,
Robert Robinson Avenue,
The Oxford Science Park,
OX4 4GA, United Kingdom;
3. Is the same GMO release planned elsewhere in the Community?
Has the same GMO been notified elsewhere by the same notifier?
GMO is a:
Identity of the GMO:
Replication-defective vector based on a lentivirus, Equine Infectious Anaemia Virus (EIAV), pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-G: rhabdovirus) envelope.
Information relating to the recipient or parental organisms from wich the GMO is derived
Equine Infectious Anaemia Virus
European Commission administrative information
Consent given by the Member State Competent Authority: